PolyPid Ltd. Ordinary Shares
PYPD Real Time Price USDRecent trades of PYPD by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by PYPD's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Compositions and methods for the treatment and prophylaxis of surgical site infections May. 07, 2024
-
Patent Title: Compositions and methods for the treatment and prophylaxis of surgical site infections Oct. 18, 2022
-
Patent Title: Methods for the treatment of peri-implantitis Sep. 01, 2020
-
Patent Title: Sustained-release drug carrier composition Jun. 16, 2020
-
Patent Title: Sustained-release drug carrier composition Nov. 05, 2019
-
Patent Title: Sustained-release drug carrier composition Oct. 23, 2018
-
Patent Title: Sustained-release nucleic acid matrix compositions Apr. 11, 2017
-
Patent Title: Sustained-release drug carrier composition Aug. 23, 2016
-
Patent Title: Compositions and methods for the treatment of bone voids and open fractures Nov. 03, 2015
-
Patent Title: Sustained-release drug carrier composition Mar. 31, 2015
-
Patent Title: Sustained-release drug carrier composition Nov. 04, 2014
-
Patent Title: Sustained-release nucleic acid matrix compositions Aug. 05, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of PYPD in WallStreetBets Daily Discussion
Recent insights relating to PYPD
Recent picks made for PYPD stock on CNBC
ETFs with the largest estimated holdings in PYPD
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PYPD Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.